Vaccine watch. HIV vaccine field trials.

D. Burke

Research output: Contribution to journalArticle

Abstract

More than a dozen different candidate HIV/AIDS vaccines have been tested and well-tolerated in uninfected human volunteers in small studies. International health agencies are therefore moving ahead to plan field efficacy trials. Scientists agree that field trials must be randomized, placebo controlled, and double-blinded. Further, trials must be conducted in populations with HIV incidence rates in the range of 1-3 new infections/100 persons/year. Given this rate of infection, 3000-5000 at risk volunteers would be needed. The need for only voluntary participation and risk-reduction education among volunteers are also considered.

Original languageEnglish (US)
Pages (from-to)9
Number of pages1
JournalAIDS & society
Volume4
Issue number2
StatePublished - Jan 1993
Externally publishedYes

Fingerprint

AIDS Vaccines
Volunteers
Vaccines
International Agencies
Risk Reduction Behavior
Infection
Placebos
HIV
Education
Incidence
Health
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vaccine watch. HIV vaccine field trials. / Burke, D.

In: AIDS & society, Vol. 4, No. 2, 01.1993, p. 9.

Research output: Contribution to journalArticle

Burke, D 1993, 'Vaccine watch. HIV vaccine field trials.', AIDS & society, vol. 4, no. 2, pp. 9.
Burke, D. / Vaccine watch. HIV vaccine field trials. In: AIDS & society. 1993 ; Vol. 4, No. 2. pp. 9.
@article{2a1528d2c65d4447a7d522c0d3f8599b,
title = "Vaccine watch. HIV vaccine field trials.",
abstract = "More than a dozen different candidate HIV/AIDS vaccines have been tested and well-tolerated in uninfected human volunteers in small studies. International health agencies are therefore moving ahead to plan field efficacy trials. Scientists agree that field trials must be randomized, placebo controlled, and double-blinded. Further, trials must be conducted in populations with HIV incidence rates in the range of 1-3 new infections/100 persons/year. Given this rate of infection, 3000-5000 at risk volunteers would be needed. The need for only voluntary participation and risk-reduction education among volunteers are also considered.",
author = "D. Burke",
year = "1993",
month = "1",
language = "English (US)",
volume = "4",
pages = "9",
journal = "AIDS & society",
issn = "1055-0380",
number = "2",

}

TY - JOUR

T1 - Vaccine watch. HIV vaccine field trials.

AU - Burke, D.

PY - 1993/1

Y1 - 1993/1

N2 - More than a dozen different candidate HIV/AIDS vaccines have been tested and well-tolerated in uninfected human volunteers in small studies. International health agencies are therefore moving ahead to plan field efficacy trials. Scientists agree that field trials must be randomized, placebo controlled, and double-blinded. Further, trials must be conducted in populations with HIV incidence rates in the range of 1-3 new infections/100 persons/year. Given this rate of infection, 3000-5000 at risk volunteers would be needed. The need for only voluntary participation and risk-reduction education among volunteers are also considered.

AB - More than a dozen different candidate HIV/AIDS vaccines have been tested and well-tolerated in uninfected human volunteers in small studies. International health agencies are therefore moving ahead to plan field efficacy trials. Scientists agree that field trials must be randomized, placebo controlled, and double-blinded. Further, trials must be conducted in populations with HIV incidence rates in the range of 1-3 new infections/100 persons/year. Given this rate of infection, 3000-5000 at risk volunteers would be needed. The need for only voluntary participation and risk-reduction education among volunteers are also considered.

UR - http://www.scopus.com/inward/record.url?scp=0027342372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027342372&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 9

JO - AIDS & society

JF - AIDS & society

SN - 1055-0380

IS - 2

ER -